Mechanisms by which diabetes increases cardiovascular disease

Drug Discovery Today: Disease Mechanisms

Volumn 4, Issue 3, 2007, Pages 131-140

  Gleissner, Christian A ^a   Galkina, Elena ^b   Nadler, Jerry L ^c   Ley, Klaus ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADIPOCYTOKINE; ADIPONECTIN; ADVANCED GLYCATION END PRODUCT; ALDOSE REDUCTASE INHIBITOR; ALPHA TOCOPHEROL; AMINOGUANIDINE; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; ATORVASTATIN; C PEPTIDE; CERIVASTATIN; CIGLITAZONE; EPALRESTAT; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN AP2; FIBRIC ACID DERIVATIVE; HEXOSAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN LIPASE; METFORMIN; PENTOXIFYLLINE; PIOGLITAZONE; POLYOL; PROTEIN KINASE C; TELMISARTAN; TERUTROBAN; THROMBOXANE A2 RECEPTOR; TROGLITAZONE; UNINDEXED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEUROPATHY; DIABETOGENESIS; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; METABOLIC SYNDROME X; MOLECULAR BIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT;

EID: 47049121292     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2007.12.005     Document Type: Review

References (75)

1. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352 (2005) 1685-1695
2. Rosamond W., et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
3. Adeghate E., et al. An update on the etiology and epidemiology of diabetes mellitus. Ann. N. Y. Acad. Sci. 1084 (2006) 1-29
4. American Diabetes Association. Standards of Medical Care in Diabetes - 2007. Diabetes Care 30 Suppl. 1 (2007) S4-S41
5. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 (2001) 813-820
6. Das Evcimen N., and King G.L. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol. Res. 55 (2007) 498-510
7. Williams M.D., and Nadler J.L. Inflammatory mechanisms of diabetic complications. Curr. Diab. Rep. 7 (2007) 242-248
8. Natarajan R., and Nadler J.L. Lipid inflammatory mediators in diabetic vascular disease. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1542-1548
9. Spycher S.E., et al. Aldose reductase induction: a novel response to oxidative stress of smooth muscle cells. FASEB J. 11 (1997) 181-188
10. Bohren K.M., et al. The aldo-keto reductase superfamily. cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases. J. Biol. Chem. 264 (1989) 9547-9551
11. Vikramadithyan R.K., et al. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J. Clin. Invest. 115 (2005) 2434-2443
12. Wu L., et al. Addition of dietary fat to cholesterol in the diets of LDL receptor knockout mice: effects on plasma insulin, lipoproteins, and atherosclerosis. J. Lipid. Res. 47 (2006) 2215-2222
13. Hotta N., et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative aldose reductase inhibitor-diabetes complications trial. Diabetes Care 29 (2006) 1538-1544
14. Oka M., and Kato N. Aldose reductase inhibitors. J. Enzyme Inhib. 16 (2001) 465-473
15. Demaine A.G. Polymorphisms of the aldose reductase gene and susceptibility to diabetic microvascular complications. Curr. Med. Chem. 10 (2003) 1389-1398
16. Srivastava S.K., et al. Hyperglycemia-induced activation of human erythrocyte aldose reductase and alterations in kinetic properties. Biochim. Biophys. Acta. 870 (1986) 302-311
17. Goldin A., et al. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114 (2006) 597-605
18. Schmidt A.M., et al. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res. 84 (1999) 489-497
19. Moore K.J., et al. Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J. Clin. Invest. 115 (2005) 2192-2201
20. Rask-Madsen C., and King G.L. Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler Thromb Vasc. Biol. 25 (2005) 487-496
21. Rahbar S., and Figarola J.L. Novel inhibitors of advanced glycation endproducts. Arch. Biochem. Biophys. 419 (2003) 63-79
22. Figarola J.L., et al. Anti-inflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes. Diabetes 56 (2007) 647-655
23. Rahbar S., et al. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin. Chim. Acta. 301 (2000) 65-77
24. Okamoto T., et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J. 16 (2002) 1928-1930
25. Bucciarelli L.G., et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106 (2002) 2827-2835
26. Wendt T., et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 185 (2006) 70-77
27. Manduteanu I., et al. High glucose induces enhanced monocyte adhesion to valvular endothelial cells via a mechanism involving ICAM-1, VCAM-1 and CD18. Endothelium 6 (1999) 315-324
28. Verrier E., et al. PPARgamma agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway: role of diacylglycerol kinase. Circ. Res. 94 (2004) 1515-1522
29. Yasunari K., et al. Mechanisms of action of troglitazone in the prevention of high glucose-induced migration and proliferation of cultured coronary smooth muscle cells. Circ. Res. 81 (1997) 953-962
30. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356 (2007) 2457-2471
31. Du X.L., et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 12222-12226
32. Du X.L., et al. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J. Clin. Invest. 108 (2001) 1341-1348
33. Duan W., et al. Distinct effects of glucose and glucosamine on vascular endothelial and smooth muscle cells: evidence for a protective role for glucosamine in atherosclerosis. Cardiovasc. Diabetol. 4 (2005) 16
34. Cyrus T., et al. Absence of 12/15-lipoxygenase expressions decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice. Circulation 103 (2001) 2277-2282
35. George J., et al. 12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice. Circulation 104 (2001) 1646-1650
36. Bleich D., et al. Resistance to type 1 diabetes induction in 12-lipoxygenase knockout mice. J. Clin. Invest. 103 (1999) 1431-1436
37. Kuhn H., et al. In vivo action of 15-lipoxygenase in early stages of human atherogenesis. J. Clin. Invest. 99 (1997) 888-893
38. Wittwer J., and Hersberger M. The two faces of the 15-lipoxygenase in atherosclerosis. Prostaglandins Leukot. Essent Fatty Acids 77 (2007) 67-77
39. Sobel B.E. Optimizing cardiovascular outcomes in diabetes mellitus. Am. J. Med. 120 Suppl. 2 (2007) S3-S11
40. Grundy S.M., et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109 (2004) 433-438
41. Kahn R., et al. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 48 (2005) 1684-1699
42. Lopes-Virella M.F., et al. The immunogenicity of modified lipoproteins. Ann. N. Y. Acad. Sci. 1043 (2005) 367-378
43. Association A.D. Dyslipidemia management in adults with diabetes. Diabetes Care 27 (2004) 68S-71S
44. Libby P., and Plutzky J. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. Am. J. Cardiol. 99 (2007) 27B-40B
45. Petersen K.F., and Shulman G.I. New insights into the pathogenesis of insulin resistance in humans using magnetic resonance spectroscopy. Obesity (Silver Spring) 14 Suppl. 1 (2006) 34S-40S
46. Kershaw E.E., and Flier J.S. Adipose Tissue as an Endocrine Organ. J. Clin. Endocrinol. Metab. 89 (2004) 2548-2556
47. Jansson P.A., et al. A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin. FASEB J. 17 (2003) 1434-1440
48. Wollesen F., et al. Insulin resistance and atherosclerosis in diabetes mellitus. Metabolism 51 (2002) 941-948
49. Ouchi N., et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100 (1999) 2473-2476
50. Okamoto Y., et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106 (2002) 2767-2770
51. Miyazaki Y., et al. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 89 (2004) 4312-4319
52. Moriuchi A., et al. Induction of human adiponectin gene transcription by telmisartan, angiotensin receptor blocker, independently on PPAR-gamma activation. Biochem. Biophys. Res. Commun. 356 (2007) 1024-1030
53. Wu K.K., et al. Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor. Atherosclerosis 181 (2005) 251-259
54. Chiba T., et al. Leptin deficiency suppresses progression of atherosclerosis in apoE-edficient mice. Atherosclerosis 196 (2008) 68-75
55. Hashimoto T., et al. Requirement of apelin-apelin receptor system for oxidative stress-linked atherosclerosis. Am. J. Pathol. 171 (2007) 1705-1712 ajpath.2007.070471
56. Fu Y., et al. The adipocyte lipid binding protein (ALBP/aP2) gene facilitates foam cell formation in human THP-1 macrophages. Atherosclerosis 165 (2002) 259-269
57. Hotamisligil G.S., et al. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 274 (1996) 1377-1379
58. Makowski L., et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat. Med. 7 (2001) 699-705
59. Furuhashi M., et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 447 (2007) 959-965
60. Llaverias G., et al. Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages. Biochem. Biophys. Res. Commun. 318 (2004) 265-274
61. Marx N., et al. C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 540-545
62. Walcher D., et al. C-Peptide induces vascular smooth muscle cell proliferation: involvement of SRC-kinase, phosphatidylinositol 3-kinase, and extracellular signal-regulated kinase 1/2. Circ. Res. 99 (2006) 1181-1187
63. Zuccollo A., et al. The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus. Circulation 112 (2005) 3001-3008
64. Belhassen L., et al. Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J. Am. Coll. Cardiol. 41 (2003) 1198-1204
65. Xu S., et al. The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice. Diabetes 55 (2006) 110-119
66. Kobayashi J., et al. Serum lipoprotein lipase mass: clinical significance of its measurement. Clin. Chim. Acta. 378 (2007) 7-12
67. Hanyu O., et al. Lipoprotein lipase (LPL) mass in preheparin serum reflects insulin sensitivity. Atherosclerosis 174 (2004) 385-390
68. Kobayashi J., et al. Lipoprotein lipase mass and activity in post-heparin plasma from subjects with intra-abdominal visceral fat accumulation. Clin. Endocrinol. (Oxf.) 48 (1998) 515-520
69. Shashkin P.N., et al. Insulin and glucose play a role in foam cell formation and function. Cardiovasc. Diabetol. 5 (2006) 13
70. Altshuler D., et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet. 26 (2000) 76-80
71. Goodarzi M.O., et al. Association of the diabetes gene calpain-10 with subclinical atherosclerosis: the Mexican-American coronary artery disease study. Diabetes 54 (2005) 1228-1232
72. Bacci S., et al. The K121Q polymorphism of the ENPP1/PC-1 gene is associated with insulin resistance/atherogenic phenotypes, including earlier onset of type 2 diabetes and myocardial infarction. Diabetes 54 (2005) 3021-3025
73. Boonyasrisawat W., et al. Tag polymorphisms at the A20 (TNFAIP3) locus are associated with lower gene expression and increased risk of coronary artery disease in type 2 diabetes. Diabetes 56 (2007) 499-505
74. Asleh R., and Levy A.P. In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease. Vasc. Health Risk Manage. 1 (2005) 19-28
75. Levy A.P., et al. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diabetes Care 27 (2004) 2767